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The European Group on  Ethics  in  Science and  New Technologies  (EGE), 
Having  regard  to  the  request  for  an  Opinion  by  the  European  Commission  of  11 
September  1998  on  amendment  N°36  tabled  by  the  European  Parliament  which 
proposes  to  exclude  from  Community  funding  research  projects  that  "result  in  the 
destruction  of human  embryos",  in  the  context  of deciding  on  the tts Framework 
Programme, 
Having  regard  to  the  Treaty  on  European  Union  as  amended  by  the  Treaty  of 
Amsterdam  to  be  ratified,  and  in  particular  Article  6  (formerly  Article  F)  of the 
common  provisions  concerning  the  respect  for  fundamental  rights,  and  the  Articles 
163-173 (formerly Articles 130f-130p) on research and technological development, 
Having  regard  to  the  proposal  for  a  European  Parliament  and  Council  Decision 
concerning  the  Fifth  Framework  Programme  of  the  European  Community  for 
Research, Technological Development and Demonstration Activities (1998 - 2002) of 
30  April  1997,  and  in  particular Article  6  concerning  compliance  with  fundamental 
ethical principles,  and  footnote  2 of Annex II on  Scientific  and  Technical objectives 
concerning ethical requirements, 
Having regard to  the Common Position of the Council of Ministers of 23  March 1998 
and  the  second reading  of the European Parliament of 17  June  1998,  concerning the 
above mentioned proposal for a Fifth Framework Programme, 
Having  regard  to  the  proposal  for  a  Council  Decision  concerning  a  specific 
programme for research, technological development and demonstration on  "Quality of 
life and management of living resources" of 10 June 1998, and in particular footnote 8 
on ethical requirements, 
Having  regard  to  Directive  98/44/EC  of  6  July  1998  on  the  legal  protection  of 
biotechnological inventions, in particular Article 6, Having  regard  to  the  Resolutions  of the  European  Parliament  namely  the  Resolution 
on  the  ethical  and  legal  problems  of  genetic  engineering,  and  the  Resolution  on 
artificial insemination  'in vivo"  and  'in vitro",  both of 16  March  1989, 
Having  regard  to  the  Council  of  Europe  Convention  on  Human  Rights  and 
Biomedicine signed  on  4 April  1997,  and  the  additional protocol to  the Convention on 
the prohibition  of cloning human beings  signed  on  12  January  1998, 
Having regard to  the  Universal Declaration on  the  Human Genome and Human Rights 
adopted by  the  General Conference of UNESCO on  11  November, 
Having  regard  to  national  regulations  and  opinions  expressed  by  national  ethical 
bodies within the European Union  on  the  use  of embryonic tissues, 
Having  regard  to  the  report  of  the  HER  working  party  (Human  Embryo  Research) 
(1993)  set up  by the  European Commission, 
Having  regard  to  the  hearing  held  on  3  November  1998  by  the  EGE,  with  experts, 
representatives  of the  European  Institutions  and  of interest groups  (health,  consumers, 
industry,  religions), 
Having heard the rapporteurs. 
1.  WHEREAS: 
SCIENTIFIC  BACKGROUND 
1.1  The  first  baby to be conceived  o~  vitro  fertilisation  (IVF)  outside  the  mother's  body 
was  not  born  until  1978  in  the  UK,  research  on  human  gametes  and  embryos  donated 
by infertile couples  had been  carried out for  the  previous  10  years.  During  this  period 
there  were no  specific regulations  concerning human embryo research. 
Different objectives of  human embryo research 
1.2  Nowadays,  human  embryo research in  which the  embryo  does  not survive is  permitted 
in  several  Member  States,  in  particular  with  the  applied  objectives  of  alleviating 
infertility  in  the  couple  or  diagnosing  serious  genetic  or  chromosomal  defects  in  the 
embryo. 
1.3  Some Member States  only allow  an  IVF embryo to  be  used  for  research if the  research 
is  intended for  the  benefit of that particular embryo,  and  if the  embryo  is  subsequently 
replaced  in  the  uterus.  If there  existed  the  possibility  that  procedures  might  damage 
the  embryo,  this  type  of experimentation  conducted  on  the  embr¥c vitro,  fetus  in 
vivo or  the  mother,  is  generally  judged  as  being  unethical.  In  practice  therefore,  the 
procedures  used  in  this  so-called  "therapeutic  research"  are  very  limited.  For  the 
purposes  of this  Opinion,  we  confine the  use  of the  term  "research"  to  experiments  on 
embryos  which are  not intended for  transfer to  the  uterus,  and which do  not  survive. 
2 1.4  In  other  Member  States,  where  research  is  authorised,  research  that  is  not  for  the 
benefit of the  particular embryo  may be  permitted under licence.  Most of this  licensed 
research  is  aimed  at  either  improving  the  success  rate  and  the  safety  of  IVF  as 
treatment for  infertility,  and  investigating the  causes  of infertility and  miscarriage. 
1.5  Other  research  projects  are  concerned  with  the  diagnosis  of genetic  or  chromosomal 
defects.  Some  Member  States  also  allow  human  embryo  research  for  the  purpose  of 
increasing know ledge of human  development. 
Common rules on research in Europe 
1.6  In  the  Member States  where  embryo  research  is  allowed,  regulations  normally  require 
that  any  embryos  used  for  research  must  not  be  implanted  in  the  uterus,  nor  may  they 
be  cultured in vitro  for  longer  than  14  days  after  fertilisation,  a  stage  that  in  normal 
development  would  mark  the  end  of  the  implantation  process  and  the  last  stage  at 
which twinning  could  occur.  Most research  projects  involve  culturing the  embryos  for 
a few  days  only. 
Research on supernumerary embryos 
1. 7  In  most cases,  couples  undergoing  IVF  treatment may  have embryos  that are  in  excess 
of  the  number  that  can  safely  be  transferred  to  the  woman's  uterus,  so-called 
supernumerary  embryos.  The  couple  may  decide  to  store  these  for  their  own  future 
use,  if cryopreservation is  an  option,  or they may donate them to  other couples,  or they 
may  donate  them  for  research,  or  they  may  decide  to  let  them  perish.  These 
supernumerary  embryos  are  the  main  source  of  embryos  contributing  to  research 
projects. 
These projects  have  a number of different aims. 
1.8  One objective is  to  increase the  "take-home baby"  rate after IVF. 
The  possible beneficial  effect of enriching  the  culture  medium  with  additives  (such  as 
growth  factors),  or  culturing  them  together  with  supporting  cells  from  the 
reproductive  tract,  can  be  assessed  by  continuing  to  grow  the  supernumerary embryos 
for  a  few  days  longer  in  vitro.  The  normality  of the  cultured  embryos  can  then  be 
assessed by biochemical studies  or chromosomal analysis. 
Another  objective  is  concerned  with  identifying  features  of the  cultured  embryos  that 
might have  predictive  value  for  subsequent developmental potential. 
3 Research  on  supernumerary  embryos  has  also  led  to  the  development  of  safe  and 
reliable  procedures  for  freezing  embryos  (  cryopreservation),  so  that  women/couples 
may increase the  chances of achieving  a successful pregnancy by choosing to  have  any 
supernumerary  embryos  transferred  to  the  uterus  at  a  later  stage.  These 
cryopreservation  methods,  developed  by  the  use  of human  embryo  research,  are  now 
routinely  used  in  clinical  practice  of most  Member  States,  and  enhance  the  success 
rate of IVF. 
1.9  Different  research  projects  on  supernumerary  embryos  have  been  carried  out  to 
establish  the  safety  for  embryo  development  of removing  one  or  more  cells  during 
embryo  cleavage  for  the  diagnosis  of serious  genetic  or chromosomal  disorders.  This 
technique  of  preimplantation  genetic  diagnosis  is  now  used  throughout  the  world. 
New  methods  of using  enzymes  or  other  gene  products  to  diagnose  genetic  diseases, 
and  more  efficient  methods  to  identify  aberrant  chromosome  constitutions,  and  to 
circumvent the problems of chromosomal mosaicism,  are under investigation. 
1.10  Other research  projects  on  supernumerary  embryos  is  carried  out  in  order to  produce 
cell  lines  (so-called  "embryonic  stem  cells")  which  are  capablen vitro  of forming 
many different cell  types  and  tissues.  Various  studies  along these lines  have  recently 
been  reported  in  the  US.  In  the  future,  such  cell  lines  may  be  of  value  in  the 
therapeutic  treatment  of damage  due  to  accident  or  degenerative  disease  affecting 
skin, heart, kidney or nervous tissue. 
Research on unfertilised eggs that are subsequently fertilised in vitro 
1.11  Other research  projects  are  carried out on  unfertilised eggs  donated for  research  and 
subsequently fertilised in vitro.  This  is  an  additional  source  of embryos  for research 
projects,  and  the  only  source  that  can  be  used  for  projects  involving  the  process  of 
fertilisation itself, or the early stages of cleavage. 
There are both clinical and ethical arguments in support of developing safe methods to 
cryopreserve unfertilised eggs  rather than  embryos, for example for their later use by 
women undergoing cancer treatment. After which, these women become sterile. 
Different protocols for  freezing  and thawing may be  followed by attempts to  fertilise 
the  eggs in  vitro.  Tests  to  see  whether  they  develop  normally  after  fertilisation  are 
carried out in vitro, as  an  alternative to transfer to the uterus with the risk of abnormal 
development in vivo. 
Other  research  projects  examine  the  safety  of removing  first  and/or  second  polar 
bodies as  a possible alternative to  embryo biopsy for  the purposes of preimplantation 
genetic diagnosis. They also analyse the risks of using immature sperm for ICSI (Intra 
Cytoplasmic Spermatid Injection) in cases of severe male infertility. 
4 With  the  aim  of m1mm1smg  the  need  for  hormone  stimulation  of  womim.,vitro 
maturation  of  immature  eggs  is  also  being  studied,  combined  with  tests  on  the 
fertilisability  of  the in  vitro  matured  eggs,  and  the  normality  of  their  subsequent 
development in vitro. 
Possible future developments 
1.12  In  the  past,  research  on  human  eggs  and  embryos,  without  any  existing  legal 
framework  at  the  time,  played  a  large  role  in  the  development  of IVF  as  a  treatment 
for  the  alleviation  of  infertility.  Today  licensed  human  embryo  research  is  more 
closely linked to  new  and constantly evolving techniques of assisted reproduction. 
In  the  near future,  other objectives  of human  embryo  research  may become  extremely 
important.  Basic  research  in  this  area  increases  our  understanding  of  early  human 
development, for example the expression of "cancer genes" in human development. 
LEGAL  BACKGROUND 
Controversies on the concept of  beginning of  life and ''personhood" 
1.13  Existing  legislation  in  the  Member  States  differs  considerably  from  one  another 
regarding the question of when life  begins  and about the definition of "personhood". 
As  a  result,  no  consensual  definition,  neither  scientifically  nor  legally,  of when  life 
begins exists. 
Two  main  views  about the  moral  status  of the  embryo  and  thus  regarding  the  legal 
protection afforded to them with respect to scientific research exist: 
•  human  embryos  are  not  considered  as  human  beings  and  consequently  have  a 
relative worth of protection; 
•  human embryos have the same moral status as  human beings and consequently are 
equally worthy of protection. 
1.14  The  discussion  of common  rules  on  embryo  research  is  continuing.  Recently  many 
European countries,  when discussing and  signing the  Council of Europe Convention 
on  Human  Rights  and  Biomedicine,  failed  to  reach  a  consensus  concerning  the 
definition  of the  embryo,  and,  therefore,  were  unable  to  find  common  ground  on 
which  to  place  the  admissibility  of human  embryo  research  within  the  Convention. 
Hence, it is up  to the Member States to legislate in this area.  Yet, nevertheless, Article 
18.1  of the Convention stipulates "where the law allows research on embrycm vitro, 
it shall ensure adequate protection of the embryo". 
5 Initial Documentation on embryo research 
1.15  The  first  important  report  published  regarding  embryo  research  was  the  Warnock 
Report  in  1984,  which  studied  this  issue  in  order  to  examine  the  social,  ethical  and 
legal  implications  and  potential  developments  in  the  field  of  human  assisted 
reproduction.  This report recommended important rules  on  embryo research. 
1.16  The  first  specific  legislation  regarding  embryo  research  was  published  in  1988  in 
Spain  on  artificial  reproduction  and  on  donation  and  use  of  human  embryos  and 
foetuses,  including  derived  tissues,  cells  and  organs.  This  permitted  for  the  first  time 
research on the "pre-embryo" ("pre-embryo is  defined as  the initial stage which  starts 
at fertilisation and lasts until  14 days  afterwards). Since then, several legislations have 
come into force,  with different approaches regarding embryo research. 
Different approaches regarding the definition of  the human embryo 
1.17  In  most  Member  States  there  is  presently  no  legal  definition  of the  human  embryo 
(Belgium,  Denmark,  Finland,  France,  Greece,  Ireland,  Italy,  Luxembourg, 
Netherlands,  Portugal  and  Sweden).  Among  those  Member  States  which  define  the 
embryo  in  their  legislation,  the  existing  definitions  vary  considerably  from  one 
country to another (Austria, Germany, Spain, United Kingdom): 
•  In  Austrian  law,  the  embryo  is  not  defined  and  the  term  "developable  cells"  is 
defined as inseminated ova and cells developed from them. 
•  The German law  defines the embryo  as  "the fertilised  human egg cell capable of 
development, from the moment of fusion of the pronuclei"; 
•  The  Spanish  law  makes  a  distinction  between  "pre-embryo"  (group  of  cells 
resulting from the fertilisation of ovum until the implantation and formation of the 
primitive streak - 14 days),  "embryo" (process of forming organs which continues 
for about two and a half months) and the "fetus" (from two and a half months on); 
•  The  British  law  defines  the  embryo  as  a  "live  embryo  where  fertilisation  is 
complete (i.e.  completion is when a two cell zygote  appears),  including an  egg in 
the process of fertilisation". 
Legal situation in the Member States 
1.18  Within the EU, there are seven countries with legislation referring to  embryo research, 
which  is  either  treated  in  a  law  regarding  specifically  the  embryo  (Germany),  or 
included  in  a  law  referring  particularly  to  medically  assisted  reproduction  (Austria, 
Denmark, France, Spain, Sweden and United Kingdom); 
The  other  eight  countries  do  not  have  legislation  referring  to  embryo  research 
(Belgium,  Finland,  Greece,  Italy,  Ireland,  Luxembourg,  Netherlands  and  Portugal); 
from  this  last  group,  there  are  countries  where  embryo  research  is  implicitly 
prohibited by the application of constitutional rules (Ireland); 
However,  five  of  these  countries  are  at  the  moment  drafting  legislation  which 
specifically  aims  to  regulate  activities  in  the  field  of  human  embryo  research 
(Belgium)  or  to  insert  embryo  research  in  the  framework  of the  medically  assisted 
reproduction law (Italy,  the Netherlands and Portugal) or,  alternatively, in the domain 
of medical research (Finland). 
6 Different scope of  national legislation 
1.19  Among  the  Member  States  with  legal  provisions  on  embryo  research,  there  are  many 
differences regarding the activities  allowed and  prohibited. 
There  are  countries  where  embryo  research  is  allowed  only  for  the  benefit  of the 
particular  embryo  (Austria,  Germany).  There  are  Member  States  where  embryo 
research  is  exceptionally  allowed  (France,  Sweden,),  or  allowed  under  strict 
conditions (Denmark,  Finland,  Spain United Kingdom). 
Diversity in applicable rules 
1.20  There  are  some  Member  States  where  embryo  research  is  only  allowed  with  the 
approval by a national authority (Finland,  Spain,  Sweden,  United  Kingdom),  and/or of 
a national or local ethics committee (Denmark,  United Kingdom). 
In  other Member  States  where  no  legal  provisions  exist,  recommendations  (which  are 
not  legally  binding)  from  national  or  local  ethics  committees  or  codes  of  practice 
promulgated by professional bodies  apply (Belgium,  Italy and Portugal). 
Common rules of  existing legislation in the Member States 
1.21  Despite the different legal approaches,  existing legislations  in  the  Member States  have 
some common principles based on  similar ethical  and  scientific  understandings  which 
lead to  common limitations  and prohibitions  on  embryo research,  such  as: 
a.  the  time limit for  the  use of human embryos - including the carrying out of research 
activities -is generally only allowed until  14 days after fertilisation; 
b.  the prohibition of genetic modification of normal pre-implanted embryos; 
c.  the  prohibition of  the creation of developing human-animal hybrids; 
d.  the prohibition to replace embryosin utero of embryos that have been previously used 
for research; 
e.  the need to  obtain the consent of each person whose gametes were used to bring about 
the creation of the embryo. 
Legal provisions laid down at European level relating to Human Embryo Research 
1.22  Some rules applicable directly or indirectly to embryo research, such as: 
The  Directive  98/44/EC  of 6  July  1998  on  the  legal  protection  of biotechnological 
inventions,  in  which  Article  6 (2)( c)  stipulates:  II ••• shall  be considered unpatentable: 
...  uses of human embryos for industrial or commercial purposes ... 
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The Council of Europe Convention on  Human Rights and Biomedicine, 4 April  1997, 
and  the  additional  protocol  to  the  Convention  on  the  prohibition  of cloning  human 
beings,  12  January  1998,  which  refers  in  Article  18.2  to  "the  prohibition  of  the 
creation  of embryos  solely for  research  purposes 
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•  The  UK  placed  a  reservation  on 
this  Article  and  therefore,  the  creation  of embryos  solely  for  research  purposes  is 
allowed but subject to  approval by its public authority. 
7 ETHICAL  BACKGROUND 
Diversity of  views 
1.23  The  diversity  of  views  regarding  the  question  whether  or  not  research  on  human 
embryos in vitro  is  morally  acceptable,  depends  on  differences  in  ethical  approaches, 
philosophical  theories  and  national  traditions,  which  are  deeply  rooted  in  European 
culture.  Two  contrasting  approaches  exist:a  deontological  approach,  in  which  duties 
and  principles  control  the  ends  and  consequences  of our  actions;  and  utilitarian  or 
consequentialist  approaches  in  which  human  actions  are  evaluated  in  terms  of means 
and ends or consequences. 
1.24  These  views  depend  on  how  the  status  of the  embryo  is  seen.  Two  tendencies  can  be 
distinguished.  One  stressing  that  atin vitro  embryo  must  be  protected  as  a  human 
being  from  the  very  beginning,  i.e.  after  an  egg  has  been  fertilised.  The  other  stating 
that the  status  of the  human embryo,  and  thus  the  degree  of protection,  depends  on  the 
stage  and  the  context of development,  for  example,  when  the  primitive  streak  appears 
after  approximately  two  weeks.  Also  the  degree  of protection  depends  on  whether  an 
embryo transfer is  intended or not. 
1.25  The  diversity  in  policies  and  regulations  concerning  embryo  research  in  the  Member 
States  of the  EU  reflects  fundamentally  differing  views  as  to  the  question  whether 
research  on  human  embryo sin  vitro  is  morally  acceptable  or  not.  The  EC  Working 
Group  on  Human  Embryos  and  Research,  set up  by  the  European  Commission,  states, 
in  its  first  Report  [  1992,3],  that  "(t)hese  views  are  fundamentally  different  and  it  is 
difficult to  see  how,  at  these  extremes,  the  differences  can  be  reconciled".  This  is  also 
reflected  in  the  different  discussions  going  on  within  the  national  ethics  committees 
that exist in  various  Member States. 
Common values 
1.26  In  spite  of  these  fundamental  differences  in  viewpoints,  there  are  some  common 
values  and  principles.  These values  and principles include: 
the respect for  human life,  from  the  embryonic  stage; 
the relief of human suffering; 
Pluralism 
the need to  garuntee the quality and  safety of medical treatment; 
freedom  of research; 
free  and informed consent of the  women or couples concerned. 
1.27  Pluralism  may  be  seen  as  a  characteristic  of  the  European  Union,  mirroring  the 
richness of its  tradition  and  asking for  mutual respect  and tolerance. 
8 Ethical questions related to research leading to the destruction of  the embryo 
1.28  IVF  technology,  as  it  is  applied  in  most  Member  States  of the  EU,  usually  entails 
having  spare  embryos,  a  decision  as  to  what  should  (not)  be  done  with  them  is 
unavoidable.  If  other  possibilities,  including  storage  (cryopreservation)  for  later 
transfer  or  donation,  cannot  be  implemented,  in  the  end  there  only  exist  two  options: 
research (leading  to  eventual destruction)  or destruction. 
1.29  In  spite  of  the  aforementioned  stipulations  on  the  Convention  of  the  Council  of 
Europe,  the  debate  continues  concerning  the  source  of  embryos  used  for  research 
purposes:  supernumerary  embryos  on  the  one  hand,  and  unfertilised  ova  that  is 
subsequently fertilised in vitro on  the  other hand. 
9 2.  THE GROUP SUBMITS THE FOLLOWING OPINION: 
2.1  In  the  preamble  it  appeared  crucial  to  recall  that  the  progress  of knowledge  of life 
sciences,  which  in  itself  has  an  ethical  value,  cannot,  in  any  case,  prevail  over 
fundamental  human  rights  and  the  respect  which  is  due  to  all  the  members  of the 
human family. 
2.2  The  human  embryo,  whatever  the  moral  or  legal  status  conferred  upon  it  in  the 
different European  cultures  and  ethical  approaches,  deserves  legal  protection.  Even  if 
taking  into  account the  continuity of human  life,  this  protection  ought to  be reinforced 
as  the embryo  and  the fetus  develop. 
2.3  The  Treaty  on  European  Union,  which  does  not  foresee  legislative  competence  in  the 
fields  of  research  and  medicine,  implies  that  such  protection  falls  within  the 
competence  of national  legislation  (as  is  the  case  for  medically  assisted  procreation 
and  voluntary interruption  of pregnancy).  However,  Community  authorities  should be 
concerned  with  ethical  questions  resulting  from  medical  practice  or  research  dealing 
with early human  development. 
2.4  However,  when  doing  so,  the  said  Community  authorities  have  to  address  these 
ethical  questions  taking  into  account  the  moral  and  philosophical  differences, 
reflected by  the  extreme diversity of legal  rules  applicable  to  human embryo  research, 
in  the  15  Member  States.  It is  not  only  legally  difficult  to  seek  harmonisation  of 
national  laws  at  Community  level,  but  because  of  lack  of consensus,  it  would  be 
inappropriate to  impose one exclusive moral code. 
2.5  The  respect  for  different  philosophical,  moral  or  legal  approaches  and  for  diverse 
national culture is  essential to  the building of Europe. 
From an  ethical point of view,  the multicultural character of European society requires 
mutual  tolerance  to  be  shown  by  the  citizens  and  political  figures  of the  European 
Nation States that have chosen uniquely to tie their destiny together,  while at the  same 
time  ensuring  mutual  respect  for  different  historical  traditions  which  are  exceedingly 
strong. 
From  a  legal  point  of  view,  this  multiculturalism  is  based  upon  Article  6  of  the 
Amsterdam  Treaty  (ex  Article  F  of the  Treaty  on  European  Union)  which  recognises 
fundamental rights at Union level notably based on "constitutional traditions common 
to  the  Member  States".  It also  declares  that  "the  Union  shall  respect  the  national 
identity of its Member States". 
2.6  It results from  the aforementioned principles, that,  in  the  scope of European research 
programmes, the question of research on the human embryo has to be approached, not 
only  with  regard  to  the  respect  for  fundamental  ethical  principles,  common  to  all 
Member States, but equally taking into consideration diverse philosophical and ethical 
conceptions, expressed through the  practices  and  the  national  regulations  in  force  in 
this field. 
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2. 7  As  for  the  scope  of  the  amendment,  concerning  the  funding  of  human  embryo 
research,  on  which  the  Group  has  been  consulted,  the  Group  is  of the  opinion  that the 
distinction  that  could  be  made  between  research  which  implies  the  destruction  of the 
embryo  and  research  that  would  enable  the  embryo  to  develop  to  full  term  would  be 
artificial.  With  a  view  to  current  knowledge  and  new  techniques,  it  would  be  an 
unacceptable risk to  implant into  a woman's uterus  an  embryo  which  previously has 
been  the  subject  of research  and  hence  may  have  been  damaged.  Consequently,  the 
amendment  in  question  proposes  not  to  finance  research  projects  at  European  level 
that ultimately end in the destruction of the embryo and in doing so,  covers practically 
all research on human embryos. 
2.8  In  the  light of the  aforementioned principles  and  specifications,  the  Group  considers 
that  according  to  the  ethical  dimension  of  the  Community's  Fifth  Framework 
Programme Community funding  should  not a priori exclude human  embryo  research 
which  is  the  object  of different  ethical  choices  in  different  countries  but  that  this 
funding should, nevertheless, only be granted under the strict conditions set out in  the 
following paragraphs. 
2.9  The respect of pluralism does  not justify iaissez-faire attitude. Therefore, the Group 
repeats the recommendation given in the Opinion n°  10 of 11  December 1997  by the 
Group  of Advisers  on  the  Ethical  Implications  of  Biotechnology  (GAEffi)  on  the 
"Ethical aspects of the Fifth Framework Programme on Research", according to which 
"particular  attention  must  be  given  to  the  ethical  evaluation  of research  projects 
concerning the most sensitive fields ...  ". 
This  presupposes  systematic  ethical evaluation,  at Community level,  of protocols  of 
research  on  human  embryos  presented  for  Community  funding.  Besides,  such  a 
recommendation could be included in the Framework Programme itself. 
2.10  However,  the  Group  considers  that  amongst  the  fundamental  ethical  principles  that 
ought to guide this  ethical evaluation,  priority should be given to  the principle of the 
respect due  to  human  life,  as  well  as,  respect regarding the consent of the  woman or 
couple concerned. 
It should also be assured that the project complies, in all circumstances, with national 
regulations,  and  that,  in  particular,  the  approval  from  the  ethical  committee(s) 
competent at national level has previously been sought. 
2.11  Moreover, according to the Group, it is crucial to place human embryo research, in the 
countries  where it is  permitted,  under strict public control,  while ensuring maximum 
transparency,  whether the  research  in  question  is  carried out  by  either the  public  or 
private sector.  Indeed,  such transparency should be  a compulsory requirement of any 
proposal  funded  by  the  5fth  Framework  Programme,  since  it  provides  the  best 
guarantee against major risks of arbitrary experimentation. 
11 2.12  However  promising  the  medical  perspectives,  recent  manipulations  of  human  stem 
cell  lines  carried  out  in  the  US  raise  a  number  of ethical  questions.  These  questions 
emphasise the urgency to  enlarge the  debate,  which  is  just getting  underway.  European 
citizens have a right to  be clearly informed about the  conflicting values  that research is 
currently  facing,  as  well  as  to  be  put  in  a  position  to  evaluate  the  responsibilities 
implied for  society  as  a whole. 
2.13  In  order to  clearly  set  out the  most  appropriate  terms  of this  debate  at  European  level, 
specific  resources  should  be  made  available  within  the  Framework  Programme,  to 
permit a global  scientific  and  ethical  evaluation  of research projects  carried  out  on  the 
human  embryo,  such  as  are  presently  performed  in  all  countries  of  the  European 
Union where it is  permitted. This evaluation  should be  made public. 
2.14  The  Group  re-affirms  the  desire,  already  expressed  in  the  aforementioned  Opinion 
n°10,  that  the  European  Commission  provides  itself  as  rapidly  as  possible  with  a 
system  of information,  which  it  seriously  lacks  at  present,  regarding  all  ethical  and 
legal aspects relative to  life sciences, at both national and international level. Without 
such  information,  the  Union  would  no  longer be  able  to  promote  the  crucial  debate 
concerning the future of our society. 
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